Table 3.
The therapeutic effects of PD-1 antibody in glioma patients.
| Glioma type | Antibody | Time to progression | Survival | References | ||
|---|---|---|---|---|---|---|
| Months | P-value | Months | P-value | |||
| HGG | Pembrolizumab (n = 24) | 1.4 | range 0.2–9.4 | 4 | range 0.5–13.8 | Reiss et al., 2017 |
| DIPG | reRT with Nivolumab vs. reRT (n = 31) | 4.2 vs. 4.1 | 0.90 | 22.9 vs. 20.4 | 0.44 | Kline et al., 2018 |
| HGG | Nivolumab with Bevacizumab (n = 50) |
4.3 | 95% CI (3.5–5.3) | 6.5 | 95% CI (6.0–8.8) | Mantica et al., 2018 |
| GBM | Nivolumab (n = 11) vs. Pembrolizumab (n = 19) | 3.8 vs. 2.3 | 0.08 | 10.9 vs. 5.3 | 0.2 | Kurz et al., 2018 |
| GBM | Nivo3 (n = 10) vs. Nivo1+Ipi3 (n = 10) vs. Nivo3+Ipi1 (n = 20) | 1.9 vs. 1.5 vs. 2.1 | 95% CI (1.3–4.6):(0.5–2.8): (1.4–2.8) | 10.4 vs. 9.2 vs. 7.3 | 95% CI (4.1–22.8: 3.9–12.7: 4.7:12.9) | Omuro et al., 2018 |
| GBM | Pembrolizumab (n = 10) | 2.6 Media OS from start of PBZ | range 0.4–11.6 | Blumenthal et al., 2016 | ||
| GBM (bMMRD) | Nivolumab (n = 2) | >9 | Bouffet et al., 2016 | |||
| GBM | Nivolumab (n = 1) | >24 | Roth et al., 2017 | |||
reRT, reirradiation; Nivo3, nivolumab 3 mg/kg every 2 weeks; Nivo1+Ipi3, nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses, then nivolumab 3 mg/kg every 2 weeks; Nivo3+Ipi1, nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks for 4 doses, then nivolumab 3 mg/kg Q2W every 2 weeks.